Table 2.
Characteristics | Good risk group (TC ≥ 200 mg/dl and TG < 150 mg/dl) (n = 60) |
Intermediate risk group TC < 200 mg/dl and TG < 150 mg/dl or TC ≥ 200 mg/dl and TG ≥ 150 mg/dl (n = 201) |
Poor risk group TC < 200 mg/dl and TG ≥ 150 mg/dl (n = 55) |
P |
---|---|---|---|---|
Age at ICI start | ||||
Median (range) | 66.0 (41.0-81.0) | 68.0 (31.0-89.0) | 69.0 (38.0-86.0) | .09 |
Sex | ||||
Female | 29 (48.3%) | 68 (33.8%) | 14 (25.5%) | .03 |
Male | 31 (51.7%) | 133 (66.2%) | 41 (74.5%) | |
Tumor type | ||||
NSCLC | 39 (65.0%) | 128 (63.7%) | 34 (61.8%) | .93 |
Others* | 21 (35.0%) | 73 (36.3%) | 21 (38.2%) | |
Treatment type | ||||
ICI | 49 (81.7%) | 174 (86.6%) | 52 (94.5%) | .09 |
ICI plus chemotherapy | 6 (10.0%) | 7 (3.5%) | 1 (1.8%) | |
ICI plus TKI | 5 (8.3%) | 20 (9.9%) | 2 (3.6%) | |
Treatment line | ||||
First | 35 (58.3%) | 105 (52.2%) | 30 (54.5%) | .70 |
≥Second | 25 (41.7%) | 96 (47.7%) | 25 (45.5%) | |
ECOG PS | ||||
0-1 | 59 (98.3%) | 178 (88.6%) | 42 (76.4%) | .01 |
≥ 2 | 1 (1.7%) | 23 (11.4%) | 13 (23.6%) | |
Metastatic sites | ||||
0-1 | 13 (21.7%) | 31 (15.4%) | 11 (20.0%) | .45 |
≥ 2 | 47 (78.3%) | 170 (84.6%) | 44 (80.0%) | |
Diagnosis of DM | ||||
No | 56 (93.3%) | 163 (81.1%) | 39 (70.9%) | .007 |
Yes | 4 (6.7%) | 38 (18.9%) | 16 (29.1%) | |
CV disease | ||||
No | 48 (80.0%) | 141 (70.2%) | 32 (58.2%) | .02 |
Yes | 11 (18.3%) | 60 (29.8%) | 23 (41.8%) | |
NA | 1 (1.7%) | 0 (0%) | 0 (0%) | |
Hypertension | ||||
No | 25 (41.7%) | 92 (45.8%) | 13 (23.6%) | .01 |
Yes | 35 (58.3%) | 109 (54.2%) | 42 (76.4%) | |
Statin use | ||||
No | 55 (91.7%) | 149 (74.1%) | 28 (50.9%) | <.001 |
Yes | 4 (6.7%) | 51 (25.4%) | 27 (49.1%) | |
NA | 1 (1.7%) | 1 (0.5%) | 0 (0%) | |
Smoking status | ||||
Current/former smoker | 37 (61.7%) | 117 (58.2%) | 21 (38.2%) | .99 |
Never | 23 (38.3%) | 75 (37.3%) | 33 (60.0%) | |
NA | 0 (0%) | 9 (4.5%) | 1 (1.8%) | |
BMI (kg/m2) | ||||
< 25 | ||||
Underweight (BMI < 18.5) |
2 (3.3%) | 6 (3.0%) | 2 (3.6%) | .31 |
Normal (18.5 ≤ BMI ≤ 24.9) |
30 (50.0%) | 108 (53.7%) | 23 (41.8%) | |
≥ 25 | ||||
Overweight (25 ≤ BMI ≤ 29.9) |
10 (16.7%) | 28 (13.9%) | 8 (14.5%) | |
Obese (BMI ≥ 30) |
15 (25.0%) | 58 (28.8%) | 22 (40.0%) | |
NA | 3 (5.0%) | 1 (0.5%) | 0 (0%) | |
BMI (kg/m2) | ||||
Median (range) | 24.1 (16.4-34.3) | 24.2 (13.5-43.2) | 25.5 (14.7-39.8) | .13 |
HDL | ||||
Median (range) | 63 (38-112) | 50 (12-87) | 40 (23-73) | <.001 |
LDL | ||||
Median (range) | 137 (78-271) | 92 (22-219) | 86 (26-133) | <.001 |
*Others: Renal cell carcinoma, melanoma, urothelial carcinoma, head and neck carcinoma, small cell lung cancer, and breast cancer.
Abbreviations: ICI: immune checkpoint inhibitor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor; ECOG PS: Performance Status according to Eastern Cooperative Oncology Group; DM: diabetes mellitus; BMI: body mass index (kg/m2); CV: cardiovascular, NA: not available.